TICKERNOMICS Sign up
Last Update: 2024-03-28 02:14:53
Celularity Inc ( CELU ) https://www.celularity.com
5.03USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
-13.28%
CELU
SPY
32.74%
-95.00%
CELU
SPY
92.93%
CELU
0.00%
SPY
224.41%
CELU
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
1005.09
1083.58
0.07
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-5.54
67.97
33.23
-5.46
0.00
-3.65
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-2621.66
4.86
-2053.26
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.27
-164.86
-192.95
0.00
Other Earnings and Cash Flow Stats:
Celularity Inc ( CELU ) Net Income TTM ($MM) is -128.66
Celularity Inc ( CELU ) Operating Income TTM ($MM) is -151.29
Celularity Inc ( CELU ) Owners' Earnings Annual ($MM) is 0.00
Celularity Inc ( CELU ) Current Price to Owners' Earnings ratio is 0.00
Celularity Inc ( CELU ) EBITDA TTM ($MM) is -227.21
Celularity Inc ( CELU ) EBITDA Margin is -2053.26%
Capital Allocation:
Celularity Inc ( CELU ) has paid 0.00 dividends per share and bought back -43.112865 million shares in the past 12 months
Celularity Inc ( CELU ) has increased its debt by 78.761 million USD in the last 12 months
Capital Structure:
Celularity Inc ( CELU ) Interest-bearing Debt ($MM) as of last quarter is 78
Celularity Inc ( CELU ) Annual Working Capital Investments ($MM) are 5
Celularity Inc ( CELU ) Book Value ($MM) as of last quarter is 30
Celularity Inc ( CELU ) Debt/Capital as of last quarter is 66%
Other Balance Sheet Stats:
Celularity Inc ( CELU ) has 0 million in cash on hand as of last quarter
Celularity Inc ( CELU ) has 84 million of liabilities due within 12 months, and long term debt 33 as of last quarter
Celularity Inc ( CELU ) has 193 common shares outstanding as of last quarter
Celularity Inc ( CELU ) has 0 million USD of preferred stock value
Academic Scores:
Celularity Inc ( CELU ) Altman Z-Score is -9.66 as of last quarter
Celularity Inc ( CELU ) Piotroski Score is 5.00 as of last quarter
Corporate Governance:
Celularity Inc ( CELU ) largest shareholder is owning shares at 0.00 ($MM) value
Kok Thay Lim(an insider) Bought 2141098 shares of Celularity Inc ( CELU ) for the amount of $5352745.00 on 2024-01-12
37.64% of Celularity Inc ( CELU ) is held by insiders, and 19.42% is held by institutions
Celularity Inc ( CELU ) went public on 2019-08-08
Other Celularity Inc ( CELU ) financial metrics:
FCF:-118.46
Unlevered Free Cash Flow:-286.93
EPS:-1.94
Operating Margin:-2621.66
Gross Profit Margin:4.86
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-1241.46
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Celularity Inc ( CELU ) :
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products. The company was founded in 1998 and is based in Florham Park, New Jersey.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.